Omixon is an ideal addition to our transplant business line. It has a comprehensive Next Generation Sequencing (NGS) portfolio, robust bioinformatics capabilities, and an innovative pipeline of solutions.
NanoTYPE HLA™, an HLA typing assay using third generation sequencing technology from Oxford Nanopore Technologies (ONT), are included in the initial phase of this process too.
Omixon's products complement our strong transplant portfolio, and our commercial organization will help to expand their global reach. Together, we aim to accelerate the introduction of more innovative products into the market.
Partnering with Omixon complements our purpose of advancing patient care through innovative specialized diagnostics and seamlessly aligns with our long-term vision and strategy. It is an excellent strategic fit.
Werfen remains steadfast in its commitment as a Specialized Diagnostics company dedicated to delivering the highest-quality diagnostics to Power Patient Care. This acquisition marks a significant milestone for Werfen, building upon the recent investment in transplant diagnostics with the acquisition of Immucor just 18 months ago.